When will QWO be available
The delayed gastric emptying that contributes to satiety and weight loss can also lead to increased gastric distension and pressure, which may trigger or worsen symptoms related to the upper gastrointestinal tract
Oral formulations were also developed.1,3,5 GLP-1 receptor monoagonists for the treatment of obesity: liraglutide and semaglutide The first molecule to be marketed for the treatment of obesity was liraglutide (LIRA), administered via daily subcutaneous injection, which became available in 2014
That framing, while not wrong, misses most of what is actually happening
However, in October 2023, Pfizer discontinued its other oral GLP-1 candidate, lotiglipron, due to elevated liver enzymes observed in clinical trials
This approach is reflected in the GLP-1 Bundle, which combines supplements studied for their potential role in glucose control, gut health, and overall balance